Chardan Capital Reiterates Buy on Ocular Therapeutix with $23 Target
Chardan Capital maintains its buy rating for Ocular Therapeutix, Inc. with a price target of $23, a 133.74% upside from the current price.
Key Points
- Chardan Capital reiterated its buy rating on Ocular Therapeutix, Inc. (OCUL) with a $23 price target on June 25, 2026.
- Chardan Capital's $23 price target implies 133.74% upside from Ocular Therapeutix, Inc.'s ($OCUL) current $9.84 share price.
- OCUL shares traded at $9.85 on Thursday, with a market cap of approximately $2.18 billion and no meaningful P/E ratio as it isn't profitable.
- Several insiders, including CEO Dr. Pravin U. Dugel, made transactions in June, and analysts like HC Wainwright & Co. and Baird also have buy ratings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Chardan Capital reiterated its buy rating on Ocular Therapeutix, Inc. (NasdaqGM: OCUL) on June 25, 2026, setting a price target of $23. Shares of the biopharmaceutical company traded around $9.85 on Thursday.
Other Institutional Activity in Ocular Therapeutix
FMR LLC increased its holdings by 868,159 shares, reaching a total of 32,653,764 shares valued at approximately $276.6 million. DEEP TRACK CAPITAL, LP made a significant addition of 11,615,868 shares, boosting its position by 143.9% to 19,686,282 shares worth about $166.7 million. BLACKROCK, INC. added 530,537 shares, resulting in a total of 16,132,931 shares valued at roughly $136.6 million. AVORO CAPITAL ADVISORS LLC also increased its position by 1,537,223 shares, ending with 12,315,000 shares valued at $104.3 million. Meanwhile, VENROCK ADVISER, LLC grew its stake by 3,031,379 shares, marking a 41.4% increase to 10,346,926 shares worth approximately $87.6 million.
Ocular Therapeutix, Inc. Stock Down 5.0%
Shares of Ocular Therapeutix, Inc. traded near $9.85 on Thursday. The company has a market cap of about $2.18 billion. It doesn't have a meaningful P/E ratio as it is not currently profitable, with an EPS of -$1.44. The stock has a 52-week low of $6.23 and a high of $16.44. The 50-day moving average stands at $9.02, while the 200-day moving average is $10.51. Ocular Therapeutix has a current ratio of 14.81, a quick ratio of 14.49, and a debt-to-equity ratio of 13.66.
$OCUL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
In its most recent earnings report, Ocular Therapeutix posted revenue of $52.04 million, reflecting a modest growth of 0.8%. The company reported a net margin of 0.0% and a return on equity of -68.55%. The next earnings release is anticipated on August 5, 2026.
Insider Buying and Selling at Ocular Therapeutix, Inc.
Several insiders at Ocular Therapeutix were active in June. CEO Dr. Pravin U. Dugel both sold and bought 50,092 shares on June 16. Adrienne Graves bought 44,000 shares on June 10, while Jason Shand Robins, the CFO, acquired 14,024 shares on the same day. Seung Suh Hong also purchased 14,000 shares on June 10.
Analysts Set New Price Targets
On June 25, 2026, Chardan Capital maintained its buy rating for Ocular Therapeutix with a $23 price target. HC Wainwright & Co. reiterated its buy rating on June 18 with a $25 target, while Baird maintained a buy rating with a $30 target on the same day. The consensus among analysts is a strong buy, with a mean target price of $26.91 based on 11 opinions.
About Ocular Therapeutix
Ocular Therapeutix, Inc. is a biopharmaceutical company based in Bedford, Massachusetts. It focuses on developing and commercializing therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology. The company markets DEXTENZA, a dexamethasone ophthalmic insert, and is working on other treatments like AXPAXLI and OTX-TIC for various eye diseases. Led by CEO Dr. Pravin U. Dugel, the company employs around 325 people.
Bottom Line
Chardan Capital's reiteration of a buy rating with a $23 target reflects ongoing confidence in Ocular Therapeutix's potential. Investors keep an eye on such analyses to gauge market sentiment, though it's important to remember that these ratings are based on past and current data. The company's next earnings report on August 5, 2026, will provide further insights into its financial health and future prospects.
Get Ocular Therapeutix, Inc. alerts
New 13F filings, insider trades, and analyst moves on $OCUL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.